Private Wealth Partners LLC Trims Stake in Pfizer Inc. (NYSE:PFE)

Private Wealth Partners LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 425,358 shares of the biopharmaceutical company’s stock after selling 43,646 shares during the quarter. Pfizer comprises 1.0% of Private Wealth Partners LLC’s portfolio, making the stock its 26th largest position. Private Wealth Partners LLC’s holdings in Pfizer were worth $12,246,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. grew its holdings in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $255,000. Brookstone Capital Management lifted its stake in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. lifted its stake in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. lifted its stake in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after buying an additional 74,487 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.6 %

Shares of Pfizer stock traded up $0.14 during trading on Friday, hitting $25.40. The stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The firm’s fifty day simple moving average is $26.96 and its 200-day simple moving average is $28.39. The stock has a market cap of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the business posted $1.14 EPS. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.